CJC-1295 No DAC is frequently described as though “No DAC” were a minor packaging detail. Scientifically, it changes which material is being discussed.
Prime Peptide lists CJC-1295 No DAC, also known as Modified GRF (1-29), as a distinct research product. That explicit naming helps buyers avoid confusing it with longer-acting DAC-linked forms.
The name carries the first scientific clue
DAC refers to a drug affinity complex designed to extend persistence through albumin binding. The No DAC form lacks that modification. Researchers therefore treat CJC-1295 No DAC as a different experimental material from DAC-linked CJC-1295.
When reviewing literature, always check which analogue was studied. A paper on a DAC-linked compound cannot automatically answer a question about Modified GRF (1-29).
What pathway is being studied?
CJC-1295 No DAC is a synthetic growth hormone-releasing hormone analogue. Research interest centres on interaction with the GHRH receptor and downstream growth-hormone signalling. Studies may examine receptor activity, pituitary-cell responses, time-course behaviour or endocrine biomarkers.
The key scientific feature is not a promised outcome; it is the analogue’s role in a defined signalling system.
Why timing matters
For pathway research, a single measurement can miss the response pattern. Sampling schedule should reflect the hypothesis. Researchers may need multiple time points to distinguish an early signal from a sustained effect.
This makes CJC-1295 No DAC a useful example of why experimental design cannot be separated from molecular identity.
Three mistakes that weaken a CJC-1295 article
- Mixing DAC and No DAC evidence.
- Describing endocrine signalling as guaranteed clinical benefit.
- Using a purity result as proof of biological potency.
What to verify in Prime Peptide’s listing
Confirm that the product page, vial and analytical record all identify CJC-1295 No DAC or Modified GRF (1-29). Review the listed strength, request the current batch record where available and follow the product-specific storage information.
Prime Peptide’s practical advantage for Indian researchers is clearer local sourcing: product-specific information, documented batches where available and secure nationwide delivery.
Analytical documentation in plain language
HPLC can support chromatographic-purity assessment. Mass spectrometry can support molecular-mass confirmation. Neither result independently establishes full sequence, sterility, biological activity, safety or efficacy.
A strong study file should contain
- the exact analogue name;
- the lot number and certificate;
- the receipt and storage record;
- the selected model and receptor-related endpoint;
- the sampling schedule and controls;
- any deviation from the protocol.
Research-use notice: CJC-1295 No DAC is supplied by Prime Peptide strictly for controlled analytical and in-vitro research. This article does not provide dosage or administration guidance.